Therapeutic Asset Ratings
368 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Pegph20
Pancreatic Neoplasm
Pancreatic Cancer Research Team
P2
CC
(46)
PROPRANOLOL
Pancreatic Neoplasm
Zealand University Hospital
P2
CC
(46)
Romiplostim
Pancreatic Neoplasm
Peking University People's Hospital
P2
CC
(46)
Shr-A1811
Pancreatic Neoplasm
Haihua Yuan
P2
CC
(46)
Shr-A1904
Pancreatic Neoplasm
Fudan University
P2
CC
(46)
Shr-A2102
Pancreatic Neoplasm
Fudan University
P2
CC
(46)
Streptozocin
Pancreatic Neoplasm
Gustave Roussy, Cancer Campus, Grand Paris
P2
CC
(46)
tqb2916
Pancreatic Neoplasm
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
P2
CC
(46)
Trilaciclib
Pancreatic Neoplasm
The Second Affiliated Hospital of Shandong First Medical University
P2
CC
(46)
Vebreltinib
Pancreatic Neoplasm
Apollomics Inc.
P2
CC
(46)
Vesanoid
Pancreatic Neoplasm
Peking University People's Hospital
P2
CC
(46)
Zanidatamab
Pancreatic Neoplasm
Haihua Yuan
P2
CC
(46)
Zentalis
Pancreatic Neoplasm
Brandon Huffman, MD
P2
CC
(46)
Zolbetuximab
Pancreatic Neoplasm
Astellas Pharma Global Development, Inc.
P2
CC
(46)
Polyiclc
Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P1/2
CC
(46)
AZD1775
Pancreatic Neoplasm
James Cleary, MD, PhD
P2
CC
(45)
CDX 1140
Pancreatic Neoplasm
Washington University School of Medicine
P2
CC
(45)
n-803
Pancreatic Neoplasm
ImmunityBio, Inc.
P2
CC
(45)
Balstilimab
Pancreatic Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P1/2
CC
(45)
Cea Car-T Cells
Pancreatic Neoplasm
Chongqing Precision Biotech Co., Ltd
P1/2
CC
(45)
Cea-Targeted Car-T
Pancreatic Neoplasm
Weijia Fang, MD
P1/2
CC
(45)
Certepetide
Pancreatic Neoplasm
Qilu Pharmaceutical Co., Ltd.
P1/2
CC
(45)
ct041 autologous car t-cell
Pancreatic Neoplasm
CARsgen Therapeutics Co., Ltd.
P1/2
CC
(45)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-31*01 (89.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (85.3%)-IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa
Pancreatic Neoplasm
Hummingbird Bioscience
P1/2
CC
(45)
ELRAGLUSIB
Pancreatic Neoplasm
Actuate Therapeutics Inc.
P2
CC
(44)
Showing 126 to 150 of 368 assets
Previous
Page 6 of 15
Next
